EGFR and non-small cell lung carcinoma: In T790M-positive NSCLC, the preferred second-line option is osimertinib [3, 6, 8], as it specifically targets the EGFR T790M mutation, which accounts for 50–60% of cases that are resistant to first- and second-generation EGFR TKIs [3, 7].